Multiple myeloma presenting with advanced renal failure: a case report and new treatment options.
The optimal induction therapy for patients presenting with newly diagnosed myeloma and advanced renal failure is not known. Previous reports on the combination of bortezomib, thalidomide, and dexamethasone (BTD) have demonstrated high response rates. Herein, we report on a patient who presented with aggressive myeloma and severe renal failure requiring hemodialysis. The patient was treated with BTD. He had a rapid response, achieved a complete response, and no longer required dialysis. We review the data on treatment approaches for patients with renal failure and focus on the use of aggressive induction therapy with novel therapeutics.
Gladney
S Pierson
SP
Atlanta Hematology & Onclogy Associates, PC, GA, USA.
Lonial
Sagar
S
Kaufman
Jonathan L
JL
D000328:Adult; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D003907:Dexamethasone / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy*; D011719:Pyrazines / Q000008:administration & dosage; D006435:Renal Dialysis; D051437:Renal Insufficiency / Q000209:etiology / Q000628:therapy*; D013792:Thalidomide / Q000008:administration & dosage
D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D003907:Dexamethasone